Can a lung fibrosis drug help miners breathe easier?
NCT ID NCT05288179
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether pirfenidone capsules can improve lung function in 272 people with pneumoconiosis, a lung disease caused by inhaling dust. Participants take the drug or a placebo three times daily for a year. The main goal is to see if lung function (measured by FVC) improves or stabilizes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pirfenidone capsules
- What this could lead to
- If it works, this could provide a treatment option to slow lung function decline in people with pneumoconiosis.
- What could go wrong
- This is a Phase 3 trial, but pneumoconiosis is a chronic, progressive disease and pirfenidone may not reverse damage. Side effects like nausea and rash are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCONIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing China-Japan Friendship Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.